source
- FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic CancerThe U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanc…fda press · 5h ago↗ source
- FDA greenlights Revolution Medicines' pancreatic cancer gamechangerFollowing dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for…Fierce Biotech · 8h ago↗ source
- Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…